Sanofi India, a Rs. 1,500 crore multinational company, has posted satisfactory growth in sales and profits during the fourth quarter ended December 2012. Its net profit increased by 24.1 per cent to Rs. 44.8 crore from Rs. 36.1 crore in the corresponding period of last year. The company's net sales improved by 18.6 per cent to Rs. 400.7 crore from Rs. 337.9 crore. Its EBDITA worked out to Rs. 88.90 crore as against Rs. 68.20 crore, representing a strong growth of 30.4 per cent.
The Board of Directors has recommended final dividend of Rs. 29 per equity share of Rs. 10 for the year ended December 2012. An interim dividend of Rs. 4 per share had been paid in August 2012. The interim and proposed final dividend will together amount to a distribution of Rs. 76 crore (excluding dividend distribution tax) constituting 43 per cent of the company's net profit excluding exceptional items.
Sanofi's net profit for the full year ended December 2012 declined by 7.6 per cent to Rs. 176.7 crore from Rs. 191.2 crore in the previous year on account of amortization costs relating to the brands, technical know-how and goodwill acquired in 2011 from Universal Medicare Pvt Ltd and lower interest income as a result of the above investment. Its net sales increased by 21.5 per cent to Rs. 1,494 crore from Rs. 1,230 crore. EBDITA surged by 11.9 per cent to Rs. 353 core from Rs. 316 crore. EPS worked out to Rs. 76.71 as against Rs. 83.01 in the previous year.
As against the equity capital of Rs. 23 crore, its reserves and surplus improved to Rs. 1,181 crore from Rs. 1,094 crore in the previous year.